DDInter957 DDInter1108
Iodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times . In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated a lower whole-body retention, indicating potentially lower risk for bone marrow toxicity . The presence of a radioligand allows monitoring of treatment response post therapy and prior to next fraction of the dose delivery which may be clinically beneficial in estimating the intensity of lesion uptakes or deciding the dose for subsequent administrations . Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs . Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver . Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared to patients receiving octreotide alone and there was evidence of an overall survival benefit .
Iodipamide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Iodipamide {u} (Compound) is included by {v} (Pharmacologic Class) X-Ray Contrast Activity
X-Ray Contrast Activity {u} (Pharmacologic Class) includes {v} (Compound) Iohexol
Iohexol {u} may lead to a major life threatening interaction when taken with {v} Lutetium Lu 177 dotatate
Iodipamide {u} (Compound) downregulates {v} (Gene) NVL
NVL {u} (Gene) is downregulated by {v} (Compound) Iohexol
Iohexol {u} may lead to a major life threatening interaction when taken with {v} Lutetium Lu 177 dotatate
Iodipamide {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lutetium Lu 177 dotatate
Iodipamide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lutetium Lu 177 dotatate
Iodipamide (Compound) binds ALB (Gene) and ALB (Gene) is bound by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Iodipamide (Compound) is included by X-Ray Contrast Activity (Pharmacologic Class) and X-Ray Contrast Activity (Pharmacologic Class) includes Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Iodipamide (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Iodipamide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Iodipamide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate